Linda Jaber Pharm. D.

Linda Jaber Pharm. D.




Pharmacy Practice

Office Location

EACPHS, Room 2134




Linda Jaber Pharm. D.

Degrees and Certifications

  • 1987 - PharmD, Wayne State University
  • 1983 - B.S. in Pharmacy, Wayne State University


  • 2014 - Medication Therapy Management, American Pharmacists Association

Positions and Employment

  • 2009-present - Professor, Wayne State University
  • 1996-2008 - Associate Professfor, Wayne State University
  • 1989-1996 - Assistant Professor, Wayne State University
  • 1987-1989 - Clinical Lecturer, Wayne State University

Awards and Honors

  • 2013 - EACPHS Research Recognition Award
  • 2009 - Mortal & Pestle Award of Excellence, Arab American Pharmacist Association
  • 2007 - Roche Preceptor of the Year Award, graduating Doctor of Pharmacy class
  • 2006 - Excellence in Research Award, The Blue Cross Blue Shield of Michigan Foundation
  • 2003 - Leadership Award for Community Research Collaboration, Arab Community Center
  • 2000 - Excellence in Teaching Award, College of Pharmacy, Wayne State University
  • 1994 - Teacher of the Year Award, 4th year BS Pharmacy Class, Wayne State University
  • 1990 - Instructor of the Year Award, Doctor of Pharmacy class, Wayne State University
  • 1986 - Wayne State University Graduate/Professional Scholarship
  • 1982 - Rho Chi Pharmaceutical Honor Society

Professional Memberships

  • 2011-present - Scientific Committee, National Arab American Medical Association 2011-present
  • 1988-present - American Diabetes Association
  • 1989, 2013 - Member, American College of Clinical Pharmacy
  • 1998 - Arab American Coalition of the American Diabetes Association
  • 1997 - Arab American Pharmacists Association
  • 1995-1998 - The Arab American Task Force of the American Diabetes Association
  • 1994 - Michigan Society of Hospital Pharmacy
  • 1994 - Michigan Pharmacists Association
  • 1992 - American Association of Colleges of Pharmacy
  • 1991-1993 - Member, Coalition for Diabetes Education & Minority Health

Areas of Expertise

  • Diabetes management
  • Clinical diabetes research
  • Epidemiology and risk factors for diabetes in Arab Americans

Recent Publications

  •  Jaber LA, Al-Kassab AS, Dallo FJ: Diabetes Mellitus among Arab Americans. In A Biopsychosocial Perspectives on Arab Americans: Culture, Development, and Health. Springer Science. September 2013.
  • El Masri D, Koscielniak N, Piatt G, DiZazzo-Miller R, Arnetz J, Jaber LA. Barriers and Facilitators to Perceived Diabetes Self-Management in Arab American Patients with Diabetes. Manuscript in submission - Clinical Diabetes.
  • Dass S, El Masri D, Burghardt K, Jaber LA. DNA Methylation, Insulin Resistance and Medication Use in Arab
    Americans with Diabetes. Manuscript in submission- Epigenomes.
  • Berlie HD, El Masri D, Smitherman H, Jaber LA. Evaluation of Clinical and Economic Outcomes of an Academic Pharmacist-Managed Diabetes Clinic. Manuscript in submission.
  • Sukkarieh-Haraty OA, Jaber L, Kharma JA, Farran N, Bassil M. Determinants of diabetes self-care in two populations of Arabs with type 2 diabetes living in their country of origin or in the United States: A Comparative Analysis. Diabetes 2019;69(suppl1)
  • Salim AM, Archer C, Tariq M, Jaber LA, Hammad A, Kilgore PE. Vaccine knowledge, awareness, and utilization among Arab-American Adults prior to hajj. ACCESS Health Journal Spring 2019:12-24.
  • Bertran E, Berlie HD, Nixon A, Jaber LA. Does dapagliflozin affect energy intake and appetite? A randomized controlled exploratory study in healthy subjects. Clinical Pharmacology in Drug Development 2019;76:182-186. doi: 10.1002/cpdd.461. [Epub ahead of print]
  • Bertran EA, Pinelli NR, El Masri D, Sills SJ, Jaber L. Self-disclosure among men and women of Arab descent: Implications for group-based health education. American Journal of Educational Research. 2018; 6(3):196-200.
  • El Masri D, Ghosh S, Jaber LA. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 2018;137:83-92.
  • Burghardt KJ, El Masri D, Dass SE, Mosa S, Jaber LA. Association between haptoglobin gene and insulin resistance in Arab Americans. Biomarkers in Medicine, 2017;11:937-945. doi: 10.2217/bmm-2017-0094.
  • Kridli S, Liu YW, Bates A, Jilian M, Hayes D, Jaber LA. Do teen mentors improve the effectiveness of a culturally-adapted lifestyle intervention in Arab American youth? A randomized, controlled study. Journal of Nursing Education and Practice 2017;7(7)119-128.
  • DiZazzo-Miller R, Pociask FD, Bertran EA, Fritz HA, Abbas M, Tarakji S, Lysack CL, Jaber LA, Arnetz J. Diabetes is devastating and insulin is a death sentence: Provider perspectives of diabetes self-management in Arab American patients. Clinical Diabetes 2017;35(1):43-50.
  • Bertran EA, Pinelli NR, Sills SJ, Jaber LA. The Arab American experience with diabetes: Perceptions, myths and implications for culturally-specific interventions. Primary Care Diabetes 2017;11:13-19.
  • Bertran EA, Berlie HD, Taylor A, Divine G, Jaber L. Diagnostic performance of A1C for diabetes in Arab versus European populations: A systematic review and meta-analysis. Diabetic Medicine 2017;34920:156-166.
  • Fritz HA, DiZazzo-Miller R, Betran EA, Pociask FD, Tarakji S, Arnetz J, Lysack CL, Jaber LA. Diabetes self-management among Arab Americans: Patient and provider perspectives. BMC International Health and Human Rights 2016;16(22), 1-7.
  • Martin ET, Kaye KS, Knott C, Nguyen H, Santarossa M, Evans R, Beltran E, Jaber L. Diabetes and risk of surgical site infection: A systematic review and meta-analysis. Infection Control & Hospital Epidemiology 2016;37(1):88-99.
  • Betran EA, Fritz HA, Abbas M, Tarakji S, DiZazzo-Miller R, Pociask FD, Lysack CL, Arnetz J, Jaber LA. The impact of Arab American culture on diabetes self-management education. The Diabetes Educator 2015; 41(6):748-54.
  • McEwen LN, Ibrahim M, Ali NM, Assaad-Khalil SH, Tantawi HR, Nasr G, Moradi SM, Misha AA, Annabi FA, Ba-Essa EM, Bahijri SM, Tuomilehto J, Jaber LA, Herman WH for the International Group for Diabetes and Ramadan (IGDR). Impact of an Individualized Type 2 Diabetes Education Program on Clinical Outcomes during Ramadan. BMJ Open Diabetes Research and Care 2015;3:e000111.
  • Salinitri FD, Pinelli NR, Martin ET, Jaber LA. Insulin resistance and secretion in Arab Americans with glucose intolerance. Diabetes Technology & Therapeutics 2013;15(11).
  • Pinelli NR, Jantz AS, Martin ET, Jaber LA. Sensitivity and specificity of glycated hemoglobin as a diagnostic test for diabetes and pre-diabetes in Arab-Americans. J Clin Endocrinol Metab 2011;96:E1680-1683.
  • Pinelli NR, Brown MB, Herman WH, Jaber LA. Family support is associated with success in achieving weight loss in a group lifestyle Intervention for diabetes prevention in Arab-Americans. Ethn Dis 2011;21:480-484.
  • Hurren, KM, Taylor TN, Jaber LA. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. Diab Res Clin Pract 2011.
  • Jaber LA, Pinelli NR, Brown MB, Funnell M, Anderson R, Hammad A, Herman WH. Feasibility of group lifestyle intervention for diabetes prevention in Arab Americans. Diabetes Res Clin Pract. 2011;91:307-315
  • Pinelli NR, Jantz A, Smith Z, Abouhassan A, Ayar C, Jaber NA, Clarke AW, Commissaris RL, Jaber LA. Effect of administration time of exenatide on satiety responses, blood glucose and adverse events in healthy volunteers. J Clin Pharmacol. 2011;51:165-172
  • Pinelli NR, Jaber LA. Practices of Arab Americans with type 2 diabetes mellitus during Ramadan. Journal of Pharmacy Practice 2011;24:211-215
  • Pinelli NR, Brown MB, Herman WH, Jaber LA. Perceived risk and the willingness to enroll in a diabetes prevention lifestyle intervention in Arab Americans. Diabetes Res Clin Pract. 2010;90:e27-29.
  • Pinelli NR, Jaber LA, Brown MB, Herman WH. Serum 25-hydroxy vitamin D and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care 2010;33:1373-1375.
  • Pinelli NR, Berlie HD, Slaughter R, Jaber LA. Risk perception for developing diabetes among pharmacists. Ann Pharmacother 2009;43:1050-1056.
  • Pinelli NR, Cha R, Brown MB, Jaber LA. “Addition of thiazolidione or exenatide to oral agents in type 2 diabetes: A meta-analysis”. Ann Pharmacol 2008;42:1541-1551.
  • Berlie HD, Herman WH, Brown MB, Hammad A, Jaber LA. “Quality of diabetes care in Arab Americans“. Diab Res Clin Pract 2008;79:249-255.
  • Berlie HD, Hammad D, Jaber LA. “The use of glucose-lowering agents and aspirin among Arab-Americans with diabetes”. Ethn Dis 2007;17:S3-42.
  • Darwish-Yassine M, Jaber LA. “Overview : Life style and health outcomes”. Ethn Dis 2007;17:S3-26
  • Berlie HD, Kalis JS, Jaber LA. “Thiazolidinediones and the risk of edema: a meta-analysis”. Diab Res Clin Pract 2007;76(2):279-289.
  • Kridli S, Herman WH, Brown MB, Fakhouri H, Jaber LA. “The prevalence of diabetes and its risk factors among Chaldean Americans”. Ethn Dis 2006;16:351-356.
  • Hammad A, Herman WH, Jaber LA. Cardiovascular risk factors in an Arab-American population in southeastern Michigan. Ethn Dis 2005;15(1 Suppl 1):S1-29.
  • Jaber LA. Diabetes and the metabolic syndrome in Arab Americans: a community-based sample. Ethn Dis 2005;15(1 Suppl 1):S1-26-S21-28.
  • Kridli SA, Herman WH, Brown M, Fakhouri H, Jaber LA. The epidemiology of diabetes and its risk factors among Chaldean Americans. Ethn Dis 2005;15(1 Suppl 1):S1-30-S31-31.
  • Jaber LA, Brown MB, Hammad A, Zhu Q, Herman WH. “The prevalence of the metabolic syndrome among Arab Americans”. Diabetes Care 2004;27:234-238.
  • Jaber LA, Brown MB, Hammad A, Zhu Q, Herman WH. “Lack of acculturation is a risk factor for diabetes in Arab immigrants in the U.S”. Diabetes Care 2003;26:2010-2014.
  • Jaber LA, Brown MB, Hammad A, Nowak SN, Zhu Q, Ghafoor A, Herman WH. “Epidemiology of diabetes among Arab Americans”. Diabetes Care 2003;26:308-13.
  • Jaber LA. “Barriers and strategies for research in Arab Americans”. Diabetes Care 2003;26:514-5. (Commentary)
  • Nowak SN, Edwards DJ, Clarke A, Anderson GD, Jaber LA. “Pioglitazone: effect on CYP3A4 activity”. J Clin Pharmacol 2002;42(12):1299-1302.
  • Nowak SN, Singh R, Clarke A, Campbell E, Jaber LA. “Metabolic control and adherence to American Diabetes Association practice guidelines in a pharmacist-managed diabetes clinic”. Diabetes Care 2002;25:1479.
  • Jaber LA. “Glyburide/glipizide combination therapy in type 2 diabetes”. J Pharm Technol 2002;18:9-12.
  • Jaber LA, Nowak SN, Slaughter R. “Efficacy of insulin-metformin combination therapy in obese patients with type 2 diabetes”. J Clin Pharmacol 2002;42:89-94.
  • Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, “Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus”. Ann Pharmacother 1997;31:671-676.
  • Halapy H., Jaber L.A. “Diabetes management: follow-up”. Ann Pharmacother 1997;31:371.
  • Jaber L.A., Ducharme M.P., Edwards D.J., Slaughter R.L, Grunberger G. "The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with NIDDM". Pharmacother 1996;16:760-768.
  • Jaber, L.A., Antal E.J., Welshman I.R. "Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with NIDDM". Ann Pharmacother 1996;30:472-475.
  • Jaber, L.A., Ducharme M.P., Halapy H. "The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with NIDDM". Therapeutic Drug Monitoring 1996;18:6-13.
  • Jaber L.A., Halapy H., Fernet M., Tummalapalli S., Diwakaran Hb. "Evaluation of a pharmaceutical care model on diabetes management". Ann Pharmacother 1996;30:238-243.
  • Jaber, L.A., Slaughter R.L., Grunberger G. "Diabetes and related metabolic risk factors among Arab Americans". Ann Pharmacother 1995;29:573-575.
  • Jaber L.A., Antal E.J., Slaughter R.L., Welshman I.R. "Comparison of pharmacokinetics and pharmacodynamics of short and long term glyburide therapy in NIDDM". Diabetes Care 1994;17:1300-1306.
  • Jaber L.A., Antal E.J., Slaughter R.L., Welshman I.R. "The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics". Eur J Clin Pharmacol 1993;45:459-463.
  • Jaber L.A., Lewis N.J.W., Slaughter R.L., Neale A.V. "The effect of stress on glycemic control in patients with type II diabetes during glyburide and glipizide therapy". J Clin Pharmacol 1993;33:239-245.
  • Jaber L.A., Melchior Wa., Rutledge D. "Possible correlation between glycemia and blood pressure in black, diabetic, hypertensive patients". Ann Pharmacother 1992;26:882-6.
  • Jaber L.A., Wenzloff N.J., Komanicky P., Antal E.J. "An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide". J Clin Pharmacol 1990;30:181-188.
  • Demers R.Y., Neale A.V., Wenzloff N.J. Gronsman K.J., Jaber L.A. "Glycosylated hemoglobin levels and self-reported stress in adults with diabetes". Behavioral Medicine 1989;15:167-172.
  • Chang F, Jaber LA, Berlie HD, O’Connell MB. “Evolution of Peroxisome Proliferator-Activated Receptor agonists”. Ann Pharmacother 2007;41:973-983.
  • Ahmed AM, Jaber LA. “Islamic pilgrimage (HAJ): Care of diabetic pilgrims. Practical Diabetology, 2003;22:41-43.
  • Nowak SN, Jaber LA. “Aspirin dose for prevention of cardiovascular disease in diabetics”. Ann Pharmacother 2003;37:116-121.
  • Jaber L.A. “Educational value of AIDA on-line”. Diabetes Technology & Therapeutics, 2000;2:338-339.
  • Melchior W.R., Jaber L.A. "Metformin: An antihyperglycemic agent for the treatment of type II diabetes". Ann Pharmacother 1996;30:158-64.
  • Calissi P.T., Jaber L.A. "Peripheral diabetic neuropathy: Current concepts in treatment". Ann Pharmacother 1995;29:769-777.
  • Jaber, L.A. "Weight control in the management of diabetes". Diabetes Spectrum 1995;8:341-342. (Commentary)
  • Melchior W., Bindlish Va., Jaber L.A. "Angiotensin converting enzyme inhibitors in diabetic nephropathy". Ann Pharmacother 1993;13:344-350.
  • Jaber L.A. "The Pharmacology of reformulated glyburide". Patient Care Clinical Focus/September 1992:29-34.
  • Jaber L.A., Bailey E, Rybak M.J. "Enoxacin: a new quinolone antibiotic". Clin Pharm 1989;8:97-107.
  • El-Masri D, Jaber LA. Efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. Diabetes 2017;67(suppl1).
  • Conger E, Berlie H, Taylor A, Divine G, Jaber LA. Diagnostic utility of A1C for diabetes in Arab- versus European-populations: A meta-analysis. Diabetes 2015;64(suppl 1):A683.
  • McEwen LN, Ibrahim M, Ali NM, Jaber LA, Herman WH. Impact of a type 2 diabetes education program on clinical outcomes during Ramadan. Diabetes 2015;64(suppl1 1):A1677.
  • Salinitri FD, Martin ET, Pinelli NR, Jaber LA. Insulin resistance and B cell dysfunction in the pathogenesis of prediabetes in Arab Americans. Diabetes 2012;61(suppl 1):A387.
  • Pinelli NR, Herman WH, Brown MB, Jaber LA. Feasibility of Diabetes Prevention in Arab Americans. Diabetes 2010;59(suppl 1):A30. 
  • Jaber LA, Brown MB, Pinelli NR, Herman WH. Feasibility of Diabetes Prevention in Arab Americans: Preliminary Findings. Diabetes 2009;58(suppl 1):A237.
  • Berlie HD, Jaber LA, Kalus JS. „Thiazolidinediones and the risk of edema: A meta-analysis“. Pharmacothera 2006.
  • Betancourt M, Slaughter RL, Nowak S, Bach D, Jaber LA. “Quality of life assessment in patients with uncontrolled type-2 diabetes”. Pharmacother 2002.
  • Jaber LA, Herman WH, Brown MB, Hammad A. “Prevalence of glucose intolerance in Arab Americans: Preliminary findings”. Diabetes 2001;50:A212.
  • Sleiman N, Jaber LA, Nowak S, Slaughter RL. “Pharmacist-directed diabetes clinic in a chain pharmacy”. Pharmacother 2001;21:1301.
  • Nowak S, Jaber LA. “Adherence to the American Diabetes Association guidelines in a pharmacist-managed diabetes clinic”. Pharmacother 2001;21:1302.
  • Jaber L.A., Slaughter SL. “Efficacy of insulin-metformin combination therapy in patients with type 2 diabetes mellitus”. Diabetes 1998;47 (suppl 1):A88.
  • Jaber L.A., Robertson J.J., Slaughter R.L., Gimotty P.A. “Evaluation of glyburide/glipizide combination therapy in the management of type-2 diabetes”. Pharmacother 1997;17:1087.
  • Weiner L.A., Halapy H., Jaber L.A. "An evaluation of the use of beta-blockers in post-myocardial infarction patients with diabetes". Pharmacother 1996;16:136.
  • Halapy H., Slaughter R.L., Jaber L.A. "Quality of life analyses in an urban diabetic population". Pharmacother 1995;15:386.
  • Jaber L.A., Halapy H., Fernet M. "The impact of pharmaceutical care on diabetes management". Pharmacother 1995;15:111.
  • Jaber L.A., Slaughter R.L. "Characterization of diabetes and impaired glucose tolerance in Arab Americans". Pharmacother 1993;13:675.
  • Jaber L.A., Ducharme M.P., Slaughter R.L., Edwards D.J. "Influence of obesity on pharmacokinetics and pharmacodynamics of glipizide in patients with NIDDM". Pharmacother 1993;13:276.
  • Ducharme M.P., Edwards D.J., Slaughter R.L., Jaber L.A. "PK and PD of glipizide after single and chronic therapy in patients with NIDDM". Clin Pharmacol Ther 1993;53:229.
  • Jaber L.A., Ducharme M.P., Slaughter R.L., Edwards D.J. "Influence of age on pharmacokinetics and pharmacodynamics of glipizide in patients with NIDDM". Pharmacother 1992;12:502.
  • Jaber L.A., Wenzloff N.J., Welshman I.R., Antal E.J. "The effect of age upon the pharmacokinetics (PK)/pharmacodynamics (PD) of glyburide (Gly) after acute and chronic administration to type II diabetic". Diabetes 1991;40:344A.
  • Jaber L.A., Slaughter R.L., Antal E.J. "Pharmacokinetics of glyburide after chronic administration in obese diabetics". Pharmacother 1991;11:103.
  • Jaber L.A., Komanicky P., Wenzloff N.J., Antal E.J. "The pharmacokinetics/pharmacodynamics of glyburide after acute and chronic administration to type II diabetics". J. Clin Pharmacol 1990;30:842.
  • Jaber L.A., Wenzloff N.J., Slaughter R.L., Neale A.V. "Possible glyburide blunting effect on stress induced hyperglycemia". Pharmacother 1990;10:254.
  • Jaber L.A., Wenzloff N.J., Komanicky P, Antal E.J. "An evaluation of the dosage equivalence of glyburide and glipizide". Clin Res 1988;36:834A.